74 related articles for article (PubMed ID: 38489912)
1. Molecular Mechanisms of Human Disease Mediated by Oncogenic and Primary Immunodeficiency Mutations in Class IA Phosphoinositide 3-Kinases.
Dornan GL; Burke JE
Front Immunol; 2018; 9():575. PubMed ID: 29616047
[TBL] [Abstract][Full Text] [Related]
2. PIK3R1 fusion drives chemoresistance in ovarian cancer by activating ERK1/2 and inducing rod and ring-like structures.
Rausio H; Cervera A; Heuser VD; West G; Oikkonen J; Pianfetti E; Lovino M; Ficarra E; Taimen P; Hynninen J; Lehtonen R; Hautaniemi S; Carpén O; Huhtinen K
Neoplasia; 2024 May; 51():100987. PubMed ID: 38489912
[TBL] [Abstract][Full Text] [Related]
3. The effects of REG4 expression on chemoresistance of ovarian cancer.
Xiang LW; Xue H; Ha MW; Yu DY; Xiao LJ; Zheng HC
J Obstet Gynaecol; 2022 Oct; 42(7):3149-3157. PubMed ID: 35929918
[TBL] [Abstract][Full Text] [Related]
4. Activation of PI3K/AKT/mTOR signaling axis by UBE2S inhibits autophagy leading to cisplatin resistance in ovarian cancer.
Zhang M; Wang J; Guo Y; Yue H; Zhang L
J Ovarian Res; 2023 Dec; 16(1):240. PubMed ID: 38115063
[TBL] [Abstract][Full Text] [Related]
5.
D'Ambrosio C; Erriquez J; Arigoni M; Capellero S; Mittica G; Ghisoni E; Borella F; Katsaros D; Privitera S; Ribotta M; Maldi E; Di Nardo G; Berrino E; Venesio T; Ponzone R; Vaira M; Hall D; Jimenez-Linan M; Paterson AL; Calogero RA; Brenton JD; Valabrega G; Di Renzo MF; Olivero M
Cells; 2020 Feb; 9(2):. PubMed ID: 32075097
[TBL] [Abstract][Full Text] [Related]
6. MiRNAs and their interplay with PI3K/AKT/mTOR pathway in ovarian cancer cells: a potential role in platinum resistance.
Gasparri ML; Besharat ZM; Farooqi AA; Khalid S; Taghavi K; Besharat RA; Sabato C; Papadia A; Panici PB; Mueller MD; Ferretti E
J Cancer Res Clin Oncol; 2018 Dec; 144(12):2313-2318. PubMed ID: 30109500
[TBL] [Abstract][Full Text] [Related]
7. γ-Glutamyl cyclotransferase contributes to tumor progression in high grade serous ovarian cancer by regulating epithelial-mesenchymal transition via activating PI3K/AKT/mTOR pathway.
Li Y; Wu T; Wang Y; Yang L; Hu C; Chen L; Wu S
Gynecol Oncol; 2018 Apr; 149(1):163-172. PubMed ID: 29429592
[TBL] [Abstract][Full Text] [Related]
8. Evolutionary states and trajectories characterized by distinct pathways stratify patients with ovarian high grade serous carcinoma.
Lahtinen A; Lavikka K; Virtanen A; Li Y; Jamalzadeh S; Skorda A; Lauridsen AR; Zhang K; Marchi G; Isoviita VM; Ariotta V; Lehtonen O; Muranen TA; Huhtinen K; Carpén O; Hietanen S; Senkowski W; Kallunki T; Häkkinen A; Hynninen J; Oikkonen J; Hautaniemi S
Cancer Cell; 2023 Jun; 41(6):1103-1117.e12. PubMed ID: 37207655
[TBL] [Abstract][Full Text] [Related]
9. Functional and regulatory impact of chimeric RNAs in human normal and cancer cells.
Mukherjee S; Mukherjee SB; Frenkel-Morgenstern M
Wiley Interdiscip Rev RNA; 2023; 14(5):e1777. PubMed ID: 36633099
[TBL] [Abstract][Full Text] [Related]
10. Targeting the PI3K/AKT/mTOR pathway in epithelial ovarian cancer, therapeutic treatment options for platinum-resistant ovarian cancer.
Rinne N; Christie EL; Ardasheva A; Kwok CH; Demchenko N; Low C; Tralau-Stewart C; Fotopoulou C; Cunnea P
Cancer Drug Resist; 2021; 4(3):573-595. PubMed ID: 35582310
[TBL] [Abstract][Full Text] [Related]
11. Pan-cancer analysis on the role of PIK3R1 and PIK3R2 in human tumors.
Liu Y; Wang D; Li Z; Li X; Jin M; Jia N; Cui X; Hu G; Tang T; Yu Q
Sci Rep; 2022 Apr; 12(1):5924. PubMed ID: 35395865
[TBL] [Abstract][Full Text] [Related]
12. Advances in ovarian cancer, from biology to treatment.
McMullen M; Karakasis K; Rottapel R; Oza AM
Nat Cancer; 2021 Jan; 2(1):6-8. PubMed ID: 35121897
[No Abstract] [Full Text] [Related]
13. Phenotypic Consequences of
Pishas KI; Cowley KJ; Pandey A; Hoang T; Beach JA; Luu J; Vary R; Smith LK; Shembrey CE; Rashoo N; White MO; Simpson KJ; Bild A; Griffiths JI; Cheasley D; Campbell I; Bowtell DDL; Christie EL
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830797
[TBL] [Abstract][Full Text] [Related]
14. Cancer-associated mutations in the p85α N-terminal SH2 domain activate a spectrum of receptor tyrosine kinases.
Li X; Lau AYT; Ng ASN; Aldehaiman A; Zhou Y; Ng PKS; Arold ST; Cheung LWT
Proc Natl Acad Sci U S A; 2021 Sep; 118(37):. PubMed ID: 34507989
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
